208 related articles for article (PubMed ID: 24617663)
1. Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein.
Brown S; Hutchinson CV; Aspinall-O'Dea M; Whetton AD; Johnson SM; Rees-Unwin K; Burthem J
Eur J Haematol; 2014 Aug; 93(2):96-102. PubMed ID: 24617663
[TBL] [Abstract][Full Text] [Related]
2. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
3. Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2.
Patel H; Marley SB; Gordon MY
Genes Chromosomes Cancer; 2006 Dec; 45(12):1121-9. PubMed ID: 16955467
[TBL] [Abstract][Full Text] [Related]
4. Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.
Gupta M; Milani L; Hermansson M; Simonsson B; Markevärn B; Syvänen AC; Barbany G
Biochem Biophys Res Commun; 2008 Feb; 366(3):848-51. PubMed ID: 18082628
[TBL] [Abstract][Full Text] [Related]
5. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
[TBL] [Abstract][Full Text] [Related]
6. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
8. The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway.
Preisinger C; Kolch W
Cell Signal; 2010 May; 22(5):848-56. PubMed ID: 20079431
[TBL] [Abstract][Full Text] [Related]
9. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
10. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
11. Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.
Trino S; De Luca L; Simeon V; Laurenzana I; Morano A; Caivano A; La Rocca F; Pietrantuono G; Bianchino G; Grieco V; Signorino E; Fragasso A; Bochicchio MT; Venturi C; Rosti G; Martinelli G; Del Vecchio L; Cilloni D; Musto P
Tumour Biol; 2016 Jan; 37(1):217-25. PubMed ID: 26194865
[TBL] [Abstract][Full Text] [Related]
12. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.
Dong R; Cwynarski K; Entwistle A; Marelli-Berg F; Dazzi F; Simpson E; Goldman JM; Melo JV; Lechler RI; Bellantuono I; Ridley A; Lombardi G
Blood; 2003 May; 101(9):3560-7. PubMed ID: 12506035
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
15. Linking miRNA regulation to BCR-ABL expression: the next dimension.
Faber J; Gregory RI; Armstrong SA
Cancer Cell; 2008 Jun; 13(6):467-9. PubMed ID: 18538729
[TBL] [Abstract][Full Text] [Related]
16. Dehydrocostus Lactone Suppresses Proliferation of Human Chronic Myeloid Leukemia Cells Through Bcr/Abl-JAK/STAT Signaling Pathways.
Cai H; Qin X; Yang C
J Cell Biochem; 2017 Oct; 118(10):3381-3390. PubMed ID: 28300289
[TBL] [Abstract][Full Text] [Related]
17. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
Patel H; Marley SB; Greener L; Gordon MY
Leukemia; 2008 Mar; 22(3):559-71. PubMed ID: 18059481
[TBL] [Abstract][Full Text] [Related]
18. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
[TBL] [Abstract][Full Text] [Related]
19. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
20. The molecular biology of chronic myeloid leukaemia.
Melo JV
Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
